E.U. Reaches Deal To Purchase Pfizer-BioNTech Coronavirus Vaccine; Developing Countries Face Challenges In Purchasing, Distributing New Vaccines; Russia Reports COVID-19 Vaccine 92% Effective But Questions Remain

POLITICO: BioNTech/Pfizer and Commission reach coronavirus vaccine deal
“BioNTech and Pfizer confirmed Wednesday that they completed a deal for the European Commission to purchase up to 300 million doses of their front-runner coronavirus vaccine. … The Commission agreed to purchase 200 million doses of the vaccine, with the option to purchase an additional 100 million, according to a company press release…” (Deutsch, 11/11).

VOA News: Developing Nations Could Lose Out in Race for Coronavirus Vaccine
“A coronavirus vaccine that has proved 90% effective after early trials has raised hopes that the global pandemic can be brought under control in the coming months. But the nature of the vaccine means that less developed health systems face major challenges rolling out any inoculation programs…” (Ridgwell, 11/11).

AP: Russia says COVID-19 vaccine is 92% effective on early data (Litvinova, 11/11).

Bloomberg: Merkel Warns of Tough Winter Ahead Even With Glimpse of Vaccine (Colitt/Delfs, 11/11).

Fast Company: Solar fridges and powdered vaccines: How to get a COVID-19 vaccine to the developing world (Peters, 11/12).

Financial Times: Fauci predicts positive data from second Covid-19 vaccine soon (Kuchler/Gross, 11/11).

Financial Times: Hungary to become first EU state to trial Russian Covid vaccine (Hopkins/Foy, 11/12).

France 24: E.U. hopes to distribute Covid-19 vaccine within months, cases surge in Italy (11/12).

The Hill: European Union to purchase 200 million doses of Pfizer coronavirus vaccine (Bowden, 11/11).

NPR: Why Poorer Countries Aren’t Likely To Get The Pfizer Vaccine Any Time Soon (Doucleff, 11/11).

Reuters: South Africa should aim to cover 10% of population via COVAX, advisors say (Winning, 11/11).

Reuters: Brazil says Chinese vaccine trial can resume after suspension (Boadle et al., 11/11).

Science: Russia’s claim of a successful COVID-19 vaccine doesn’t pass the ‘smell test,’ critics say (Cohen, 11/11).

Washington Post: Vaccines have never been distributed equally. A coronavirus vaccine would be no different, history suggests (Mellen, 11/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.